#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	18008	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2062	861.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1422	1422	C	1040	C,T	1000,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	18008	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2062	861.1	0	HET	.	.	.	C519T	.	519	519	C	757	757	C	1007	C,T	748,211	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	33116	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3516	933.0	0	.	n	.	0	T695C	SNP	695	695	T	987	987	C	1039	C,T	988,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	33116	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3516	933.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1629	1629	A	1121	A,G	1069,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	33116	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3516	933.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2263	2263	C	1013	C	964	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	33116	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3516	933.0	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2889	2889	T	962	T,C	928,4	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	33116	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3516	933.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2337	2337	A	1053	A	1015	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	33116	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3516	933.0	0	HET	.	.	.	G540A,C	.	540	540	G	832	832	G	1172	G,A,C	840,269,1	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2246	folP	852	852	100.0	folP.l15.c4.ctg.1	1573	141.4	1	SNP	p	R228S	1	.	.	682	684	AGC	962	964	AGC	211;212;216	A;G;C,A	210;209;208,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6840	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3303	205.0	1	SNP	p	S91F	0	.	.	271	273	TCC	581	583	TCC	228;223;222	T;C;C	223;219;216	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6840	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3303	205.0	1	SNP	p	D95N	0	.	.	283	285	GAC	593	595	GAC	223;225;228	G,T;A;C	212,1;215;221	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6840	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3303	205.0	1	SNP	p	D95G	0	.	.	283	285	GAC	593	595	GAC	223;225;228	G,T;A;C	212,1;215;221	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1892	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1357	138.1	0	.	p	.	0	A39T	NONSYN	115	117	GCC	495	497	ACC	200;202;200	A;C;C	185;194;192	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1892	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1357	138.1	0	.	p	.	0	R44H	NONSYN	130	132	CGC	510	512	CAC	197;197;197	C;A;C	191;188;192	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1892	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1357	138.1	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	693	695	CAC	215;218;218	C,T;A;C	206,1;206;211	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1892	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1357	138.1	1	SNP	p	G45D	0	.	.	133	135	GGC	513	515	GGC	198;199;199	G;G,A;C,A	191;188,1;191,1	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1166	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1059	108.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5692	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2994	188.4	1	SNP	p	D86N	0	.	.	256	258	GAC	603	605	GAC	223;221;220	G;A;C	218;211;213	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5692	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2994	188.4	1	SNP	p	S87R	0	.	.	259	261	AGT	606	608	AGT	222;222;225	A,C;G;T	216,1;216;216	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5692	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2994	188.4	1	SNP	p	S87W	0	.	.	259	261	AGT	606	608	AGT	222;222;225	A,C;G;T	216,1;216;216	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5692	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2994	188.4	1	SNP	p	S87I	0	.	.	259	261	AGT	606	608	AGT	222;222;225	A,C;G;T	216,1;216;216	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5692	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2994	188.4	1	SNP	p	S88P	0	.	.	262	264	TCC	609	611	TCC	226;226;223	T;C;C	221;217;222	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5078	parE	1986	1986	100.0	parE.l15.c30.ctg.1	2645	190.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1498	1500	GGC	271;268;268	G;G;C,T,G	258;256;255,1,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4468	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2188	200.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1196	1198	GCA	249;250;250	G;C,A;A	234;233,1;235	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4468	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2188	200.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1199	1201	ATC	251;248;248	A;T;C	238;231;236	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4468	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2188	200.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1211	1213	GTG	241;237;244	G;T,G;G	229;224,1;232	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4468	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2188	200.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1211	1213	GTG	241;237;244	G;T,G;G	229;224,1;232	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4468	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2188	200.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1715	1717	ACC	196;195;194	A,G;C;C	181,1;186;184	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4468	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2188	200.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1769	1771	GCG	202;198;199	G;C;G,T	183;158;180,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4468	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2188	200.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1769	1771	GCG	202;198;199	G;C;G,T	183;158;180,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4468	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2188	200.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1892	1894	GGC	178;178;175	G,A;G;C	166,1;166;163	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4468	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2188	200.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1901	1903	GGC	160;158;155	G,T;G;C	149,1;150;148	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4468	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2188	200.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1919	1921	CCG	129;133;131	C,G;C,G;G,C	114,3;119,1;116,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6578	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3133	208.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1629	1631	CTG	218;217;218	C;T;G,T	206;203;208,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2988	porA	1146	1146	99.83	porA.l6.c4.ctg.1	1801	163.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	502	502	C	197	C	181	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3068	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1585	192.0	0	.	p	.	0	E48G	NONSYN	142	144	GAA	463	465	GGA	247;248;246	G;G;A	241;240;238	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3068	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1585	192.0	0	.	p	.	0	F135L	NONSYN	403	405	TTT	724	726	CTT	214;214;213	C;T,C;T	210;209,1;209	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3068	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1585	192.0	0	.	p	.	0	R143G	NONSYN	427	429	AGA	748	750	GGA	231;230;228	G;G;A	225;226;219	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3068	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1585	192.0	0	.	p	.	0	D171G	NONSYN	511	513	GAT	832	834	GGT	238;238;241	G;G;T,G	222;228;214,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3068	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1585	192.0	0	.	p	.	0	G189S	NONSYN	565	567	GGC	886	888	AGC	243;243;240	A,C;G;C	233,2;228;228	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3068	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1585	192.0	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	952	952	T	229	T	221	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3068	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1585	192.0	1	SNP	p	G120K	0	.	.	358	360	GGT	679	681	GGT	207;205;205	G;G;T	202;199;197	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3068	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1585	192.0	1	SNP	p	A121N	0	.	.	361	363	GCC	682	684	GCC	203;201;199	G;C;C	196;196;196	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3068	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1585	192.0	1	SNP	p	A121D	0	.	.	361	363	GCC	682	684	GCC	203;201;199	G;C;C	196;196;196	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11474	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4832	235.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1980	1982	AAT	262;266;266	A,C;A;T	251,1;254;254	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1234	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1034	118.1	1	SNP	p	V57M	1	.	.	169	171	ATG	546	548	ATG	264;263;264	A;T;G	256;255;254	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
